These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22561391)

  • 1. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials.
    Tu J; Chen Z
    Biom J; 2024 Jan; 66(1):e2200189. PubMed ID: 38047521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
    Zhang Y; Kutner M; Chen Z
    Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
    Wheeler GM; Sweeting MJ; Mander AP
    Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
    Tighiouart M; Liu Y; Rogatko A
    PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
    Chen Z; Krailo MD; Azen SP; Tighiouart M
    Contemp Clin Trials; 2010 Sep; 31(5):473-82. PubMed ID: 20609419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
    Mauguen A; Le Deley MC; Zohar S
    Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
    Tighiouart M; Piantadosi S; Rogatko A
    Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
    Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J
    PLoS One; 2017; 12(1):e0170187. PubMed ID: 28125617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.
    Ji L; Lewinger JP; Krailo M; Groshen S; Conti DV; Asgharzadeh S; Sposto R
    Pharm Stat; 2019 Nov; 18(6):659-670. PubMed ID: 31237419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.
    Dejardin D; Lesaffre E; Hamberg P; Verweij J
    Pharm Stat; 2014; 13(3):196-207. PubMed ID: 24715683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.